BR112020010473A2 - métodos de cultura celular - Google Patents

métodos de cultura celular Download PDF

Info

Publication number
BR112020010473A2
BR112020010473A2 BR112020010473-6A BR112020010473A BR112020010473A2 BR 112020010473 A2 BR112020010473 A2 BR 112020010473A2 BR 112020010473 A BR112020010473 A BR 112020010473A BR 112020010473 A2 BR112020010473 A2 BR 112020010473A2
Authority
BR
Brazil
Prior art keywords
cysteine
cystine
seq
sequence
cell culture
Prior art date
Application number
BR112020010473-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Valentine Chevallier
Nadine Kochanowski
Laetitia Malphettes
Vincent Adolphe Carol COOL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60629439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020010473(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of BR112020010473A2 publication Critical patent/BR112020010473A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112020010473-6A 2017-12-01 2018-11-29 métodos de cultura celular BR112020010473A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17204978.5A EP3492582A1 (en) 2017-12-01 2017-12-01 Cell culture methods
EP17204978.5 2017-12-01
PCT/EP2018/083010 WO2019106091A1 (en) 2017-12-01 2018-11-29 Cell culture methods

Publications (1)

Publication Number Publication Date
BR112020010473A2 true BR112020010473A2 (pt) 2020-11-24

Family

ID=60629439

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020010473-6A BR112020010473A2 (pt) 2017-12-01 2018-11-29 métodos de cultura celular

Country Status (14)

Country Link
US (1) US11859203B2 (https=)
EP (2) EP3492582A1 (https=)
JP (1) JP7422072B2 (https=)
KR (1) KR20200092348A (https=)
CN (1) CN111417715B (https=)
BR (1) BR112020010473A2 (https=)
CA (1) CA3083680A1 (https=)
EA (1) EA202091349A1 (https=)
ES (1) ES2963653T3 (https=)
HR (1) HRP20231175T1 (https=)
HU (1) HUE063812T2 (https=)
PL (1) PL3717631T3 (https=)
SG (1) SG11202004935UA (https=)
WO (1) WO2019106091A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
CN112391350A (zh) * 2020-10-30 2021-02-23 北京双鹭药业股份有限公司 高效表达抗egfr单克隆抗体细胞的筛选培养方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
EP4166651A1 (en) 2021-10-18 2023-04-19 Evonik Operations GmbH Methods and composition to increase cellular glutathione level
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition
EP4484567A4 (en) * 2022-02-21 2026-04-01 Chugai Pharmaceutical Co Ltd PERFUSION CULTURE METHOD
WO2024024720A1 (ja) * 2022-07-25 2024-02-01 味の素株式会社 細胞培養用の培地

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
CN101332157B (zh) * 1998-10-09 2012-01-11 味之素株式会社 半胱氨酸衍生物
KR20050070512A (ko) 2003-12-30 2005-07-07 삼성정밀화학 주식회사 재조합 단백질의 생산성을 증가시키는 무혈청 배지 및동물세포 배양방법
TWI456062B (zh) * 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
AU2011246502B2 (en) 2010-04-26 2014-08-28 Novartis Ag Improved cell cultivation process
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
BR112016027797A2 (pt) 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína
US11220668B2 (en) * 2016-04-28 2022-01-11 Merck Patent Gmbh Method for reducing the trisulfide level in proteins
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods

Also Published As

Publication number Publication date
PL3717631T3 (pl) 2024-03-04
JP7422072B2 (ja) 2024-01-25
EA202091349A1 (ru) 2020-08-20
US20200308536A1 (en) 2020-10-01
SG11202004935UA (en) 2020-06-29
EP3717631A1 (en) 2020-10-07
US11859203B2 (en) 2024-01-02
CA3083680A1 (en) 2019-06-06
JP2021503938A (ja) 2021-02-15
HRP20231175T1 (hr) 2024-01-19
KR20200092348A (ko) 2020-08-03
WO2019106091A1 (en) 2019-06-06
EP3717631B1 (en) 2023-08-30
CN111417715B (zh) 2024-08-27
CN111417715A (zh) 2020-07-14
HUE063812T2 (hu) 2024-02-28
EP3717631C0 (en) 2023-08-30
ES2963653T3 (es) 2024-04-01
EP3492582A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
BR112020010473A2 (pt) métodos de cultura celular
ES2908067T3 (es) Métodos para modular los perfiles de galactosilación proteicos de proteínas recombinantes empleando peracetil galactosa
US20250066832A1 (en) Cell culture methods
BRPI0818674B1 (pt) Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
US20230348850A1 (en) Cell culture processes
US20240425894A1 (en) Cell culture processes
BR122024024868A2 (pt) Métodos de cultura celular
EA044551B1 (ru) Способы культивирования клеток
BR112018007590B1 (pt) Método para produzir proteína de fusão que tem domínio fc de igg

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2803 DE 24-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.